468 related articles for article (PubMed ID: 24519384)
1. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
2. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
4. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
[TBL] [Abstract][Full Text] [Related]
5. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
6. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
7. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
8. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
[TBL] [Abstract][Full Text] [Related]
9. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
10. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
12. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
13. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
14. [Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid].
Schönfeld J; Zotz R; Mahl M; Beste M; Breuer N; Goebell H
Z Gastroenterol; 1996 Feb; 34(2):123-7. PubMed ID: 8659187
[TBL] [Abstract][Full Text] [Related]
15. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
[TBL] [Abstract][Full Text] [Related]
16. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
17. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
18. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
[TBL] [Abstract][Full Text] [Related]
19. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
[TBL] [Abstract][Full Text] [Related]
20. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
